A Phase IIb Open Label Study of BI 207127 in Combination With Faldaprevir and Ribavirin in Patients With Moderate Hepatic Impairment (Child-Pugh B) With Genotype 1b Chronic Hepatitis C Infection
Phase of Trial: Phase II
Latest Information Update: 01 Jul 2019
At a glance
- Drugs Deleobuvir (Primary) ; Faldaprevir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms HCVerso-3
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 01 Jul 2019 This trial has been Discontinued in UK - MHRA, according to European Clinical Trials Database.
- 30 Oct 2014 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 09 Jul 2014 Planned End Date changed from 1 Jan 2015 to 1 Oct 2014, as per ClinicalTrials.gov record.